Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Stock Information for Prelude Therapeutics Incorporated

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Prelude Therapeutics Incorporated

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
Prelude Announces Presentations at 2025 AACR Annual Meeting
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.